96
|
275
|
7ahjA |
Crystal structure of ppargamma v290m mutant ligand binding domain in complex with farglitazar |
100
|
273
|
6l89A |
Human ppargamma ligand binding domain complexed with butyrolactone 1 |
103
|
273
|
6l8bA |
The ligand-free structure of human ppargamma lbd |
99
|
273
|
6tsgA |
Crystal structure of peroxisome proliferator-activated receptor gamma (pparg) in complex with tetrac |
98
|
275
|
6y3uA |
Crystal structure of ppargamma in complex with compound (r)-16 |
97
|
271
|
6onjA |
Crystal structure of ppargamma ligand binding domain in complex with trap220 peptide and agonist rosiglitazone |
3
|
13
|
6pdzC |
Crystal structure of ppargamma ligand binding domain in complex with smrt peptide and inverse agonist t0070907 |
96
|
271
|
6pdzA |
Crystal structure of ppargamma ligand binding domain in complex with smrt peptide and inverse agonist t0070907 |
97
|
275
|
6oniB |
Crystal structure of ppargamma ligand binding domain in complex with n-cor peptide and inverse agonist t0070907 |
2
|
14
|
6onjC |
Crystal structure of ppargamma ligand binding domain in complex with trap220 peptide and agonist rosiglitazone |
4
|
13
|
6oniD |
Crystal structure of ppargamma ligand binding domain in complex with n-cor peptide and inverse agonist t0070907 |
93
|
268
|
6t9cA |
Crystal structure of the complex between ppargamma lbd and the ligand nv1346 (3a) |
99
|
269
|
6jeyA |
Covalent bond formation between ynone moiety of synthetic fatty acid and hpparg-lbd |
91
|
269
|
6jf0A |
Covalent labeling of hpparg-lbd by turn-on fluorescent probe mediated by conjugate addition and cyclization |
102
|
273
|
6ktmA |
The ligand-free structure of human ppargamma ligand-binding domain r288a mutant in the presence of the src-1 coactivator peptide |
99
|
272
|
6ktnA |
Human ppargamma ligand-binding domain r288a mutant in complex with imatinib |
95
|
268
|
6qj5A |
X-ray structure of ppargamma lbd with the ligand nv1380 |
3
|
11
|
6ktnB |
Human ppargamma ligand-binding domain r288a mutant in complex with imatinib |
3
|
10
|
6ktmB |
The ligand-free structure of human ppargamma ligand-binding domain r288a mutant in the presence of the src-1 coactivator peptide |
101
|
275
|
6t6bA |
Crystal structure of ppargamma in complex with compound 16 (mf27) |
98
|
268
|
6o67A |
Crystal structure of human ppargamma ligand binding domain in complex with mitoglitazone |
91
|
270
|
6o68A |
Crystal structure of human ppargamma ligand binding domain in complex with ciglitazone |
101
|
273
|
6k0tA |
Crystal structure of ppargamma ligand binding domain in complex with dibenzooxepine derivative compound-17 |
1
|
10
|
6k0tB |
Crystal structure of ppargamma ligand binding domain in complex with dibenzooxepine derivative compound-17 |
101
|
271
|
6jq7A |
The ligand-free structure of human ppargamma lbd in the presence of the src-1 coactivator peptide |
3
|
11
|
6jq7B |
The ligand-free structure of human ppargamma lbd in the presence of the src-1 coactivator peptide |
2
|
9
|
6ijrB |
Human ppargamma ligand binding domain complexed with sb1495 |
95
|
281
|
6ijrA |
Human ppargamma ligand binding domain complexed with sb1495 |
3
|
11
|
6ijsB |
Human ppargamma ligand binding domain complexed with sb1494 |
101
|
274
|
6ijsA |
Human ppargamma ligand binding domain complexed with sb1494 |
1
|
11
|
6icjB |
Crystal structure of ppargamma with compound br102375k |
2
|
14
|
6ilqB |
Crystal structure of ppargamma with compound br101549 |
97
|
271
|
6icjA |
Crystal structure of ppargamma with compound br102375k |
93
|
270
|
6ilqA |
Crystal structure of ppargamma with compound br101549 |
106
|
271
|
5z6sA |
Crystal structure of the ppargamma-lbd complexed with compound ds-6930 |
1
|
10
|
6ad9B |
Crystal structure of ppargamma ligand binding domain in complex with dibenzooxepine derivative compound-9 |
101
|
269
|
6ad9A |
Crystal structure of ppargamma ligand binding domain in complex with dibenzooxepine derivative compound-9 |
102
|
271
|
5z5sA |
Crystal structure of the ppargamma-lbd complexed with compound 13ab |
100
|
268
|
6mczA |
Crystal structure of human ppargamma ligand binding domain in complex with arachidonic acid |
97
|
268
|
6md2A |
Crystal structure of human ppargamma ligand binding domain in complex with gw9662 and arachidonic acid |
98
|
268
|
6md4A |
Crystal structure of human ppargamma ligand binding domain in complex with rosiglitazone and oleic acid |
95
|
269
|
6md1A |
Crystal structure of human ppargamma ligand binding domain in complex with gw9662 and oleic acid |
99
|
268
|
6md0A |
Crystal structure of human ppargamma ligand binding domain in complex with oleic acid |
95
|
272
|
6e5aA |
Pparg in complex with compound 4b |
95
|
270
|
6c1iA |
Crystal structure of human ppargamma ligand binding domain in complex with t0070907 |
93
|
270
|
6dhaA |
Crystal structure of human ppargamma ligand binding domain in complex with hydroxy pioglitazone (m-iv) |
108
|
276
|
6fzgA |
Ppar gamma mutant complex |
90
|
276
|
6fzyA |
Ppar mutant |
1
|
9
|
6fzpC |
Ppar gamma complex |
2
|
13
|
6fzfC |
Ppar mutant complex |